04 October 2018
DUBLIN--(BUSINESS WIRE)--Sep 27, 2018--The “Biologics Global Market Opportunities And Strategies To 2021” report has been added to ResearchAndMarkets.com’s offering.
The global biologics market was worth $221 billion in 2017 and is essentially segmented into monoclonal antibodies, therapeutic proteins and vaccines.
Biologics are very large complex molecules manufactured in a living system such as microorganisms, animal cells or plant cells. They are produced using the recombinant DNA technology and are composed of sugars, proteins, nucleic acids or a combination of these substances. In 2017, 12 biologics were approved in the USA, 10 in European Union and 7 in Japan.
There are over 1000 biologics under development which will drive the biologics market in the future. Cancer is the therapeutic area with maximum number of biologics under development and Alzheimer’s has the least number.
The number of biosimilars being approved is on the rise and is likely to affect the overall growth of biologics market globally, by expanding the market, but also by reducing average pricing. Currently, the ratio of biosimilars to biologics sold is quite similar in European Union (EU) and the USA (4% biosimilars and 96% biologics). In Japan and India, the proportion of biosimilars is higher in these markets, almost 13-19%, compared to EU and the USA.Print
10 July 2020
10 July 2020
09 July 2020
08 July 2020